In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers Squibb

This article was originally published in The Gray Sheet

Executive Summary

Reducing worldwide work force by "approximately 5,000" employees "during the next two years," the company announced Jan. 4. The reductions include 1,500 employees who accepted an early retirement program for U.S. employees announced in September ("The Gray Sheet" Sept. 27, In Brief). The bulk of the cuts (3,000 of the 5,000) are coming from the firm's pharmaceuticals group, which is being reorganized. The remaining 2,000 cuts, including approximately 800 early retirements, will affect the firm's three other businesses -- medical devices, nutritionals and consumer products -- as well as headquarters staff. The RIF/restructuring is expected to be covered by an $890 mil. charge BMS took in the fourth quarter of 1992 for the early retirement program and a 2,200 RIF announced in October 1992



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts